Cantor Fitzgerald Comments on Disc Medicine FY2025 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Disc Medicine in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings of ($5.24) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $85.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

Several other analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $118.00 target price on shares of Disc Medicine in a report on Tuesday. Raymond James raised Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $66.00 to $110.00 in a report on Monday, November 4th. Wedbush reaffirmed an “outperform” rating and set a $90.00 target price (up from $83.00) on shares of Disc Medicine in a report on Tuesday. Scotiabank raised their target price on Disc Medicine from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Wednesday. Finally, Jefferies Financial Group assumed coverage on Disc Medicine in a report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $88.50.

Disc Medicine Stock Down 3.3 %

Shares of IRON opened at $58.50 on Wednesday. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -14.70 and a beta of 0.75. Disc Medicine has a 52 week low of $25.60 and a 52 week high of $77.60. The stock’s 50-day moving average price is $62.73 and its 200-day moving average price is $53.69.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.15.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its position in Disc Medicine by 66.0% in the fourth quarter. SG Americas Securities LLC now owns 8,076 shares of the company’s stock valued at $512,000 after purchasing an additional 3,212 shares during the period. JPMorgan Chase & Co. raised its position in Disc Medicine by 16.1% in the third quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company’s stock valued at $799,000 after purchasing an additional 2,257 shares during the period. Exome Asset Management LLC grew its stake in shares of Disc Medicine by 5.8% in the third quarter. Exome Asset Management LLC now owns 64,516 shares of the company’s stock valued at $3,170,000 after buying an additional 3,516 shares in the last quarter. Teachers Retirement System of The State of Kentucky grew its stake in shares of Disc Medicine by 38.7% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 19,560 shares of the company’s stock valued at $961,000 after buying an additional 5,458 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Disc Medicine by 17.6% in the third quarter. Geode Capital Management LLC now owns 474,719 shares of the company’s stock valued at $23,333,000 after buying an additional 70,983 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Insider Transactions at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 12,791 shares of Disc Medicine stock in a transaction on Monday, December 16th. The stock was sold at an average price of $66.01, for a total value of $844,333.91. Following the sale, the chief executive officer now owns 72,065 shares in the company, valued at $4,757,010.65. The trade was a 15.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William Richard White sold 7,136 shares of Disc Medicine stock in a transaction on Monday, November 4th. The shares were sold at an average price of $58.61, for a total value of $418,240.96. The disclosure for this sale can be found here. Insiders have sold 85,758 shares of company stock valued at $5,400,990 over the last ninety days. Insiders own 4.24% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.